Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Oesophagogastric Cancer × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13 Colorectal Neoplasms 6 Stomach Neoplasms 5 Neoplasm Metastasis 4 Biliary Tract Neoplasms 4 Pancreatic Neoplasms 3 Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Rectal Neoplasms 2 Colonic Neoplasms 2 Adenocarcinoma Of Esophagus 2 Resected Liver Metastases From Colorectal Cancer 1 Recurrence 1 Quality of Life 1 Oesophagogastric Cancer 1 Inflammatory Breast Neoplasms 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 Gastroesophageal Junction Adenocarcinoma 1 Gallbladder Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Cholangiocarcinoma 1 Breast Diseases 1 Bile Duct Neoplasms 1 Anus Neoplasms 1 Adenocarcinoma 1

Interventions

Neoadjuvant Therapy 1 Lapatinib 1 Epirubicin 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown

Gastrointestinal

Oesophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡